Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Completed

Conditions: Adult Mixed Cellularity Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Adult Lymphocyte Predominant Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma

Interventions: Biological: monoclonal antibody SGN-30
Other: placebo
Drug: vinorelbine tartrate
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-06-15

Last Posted Date: 2015-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00337194

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-06-15

Last Posted Date: 2015-08-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00337129

Locations: 🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
🇺🇸
Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States

and more 135 locations

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Recurrent Nasopharyngeal Undifferentiated Carcinoma
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7

Interventions: Drug: Azacitidine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vorinostat

First Posted Date: 2006-06-12

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00336063

Locations: 🇸🇬
National University Hospital Singapore, Singapore, Singapore
🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Phase 1

Completed

Conditions: Recurrent Cervical Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Vaginal Cancer
Recurrent Vulvar Cancer
Stage III Vaginal Cancer
Stage IIIA Cervical Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIB Ovarian Epithelial Cancer
Stage IIIB Vulvar Cancer
Stage IIIC Ovarian Epithelial Cancer

Interventions: Drug: triapine
Other: laboratory biomarker analysis
Radiation: external beam radiation therapy
Radiation: brachytherapy
Drug: cisplatin
Other: pharmacological study

First Posted Date: 2006-06-12

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00335998

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Phase 2

Completed

Conditions: Precancerous Condition
Rectal Cancer
Colon Cancer

Interventions: Drug: atorvastatin calcium
Drug: sulindac
Drug: oligofructose-enriched inulin
Drug: placebo
Other: laboratory biomarker analysis

First Posted Date: 2006-06-12

Last Posted Date: 2017-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT00335504

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Tumor
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Drug: sorafenib tosylate
Drug: erlotinib hydrochloride
Drug: temsirolimus
Drug: tipifarnib

First Posted Date: 2006-06-12

Last Posted Date: 2018-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00335764

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-06-08

Last Posted Date: 2017-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00334893

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Lung Adenocarcinoma
Lung Large Cell Carcinoma
Lung Squamous Cell Carcinoma
Minimally Invasive Lung Adenocarcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Lung Adenosquamous Carcinoma

Interventions: Drug: Cisplatin
Biological: Bevacizumab
Drug: Docetaxel
Drug: Etoposide
Biological: Filgrastim
Biological: Pegfilgrastim
Radiation: Radiation Therapy

First Posted Date: 2006-06-08

Last Posted Date: 2025-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00334815

Locations: 🇺🇸
Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton, Massachusetts, United States
🇺🇸
Fremont - Rideout Cancer Center, Marysville, California, United States
🇺🇸
Providence Hospital, Mobile, Alabama, United States

and more 60 locations

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Adult Solid Neoplasm

Interventions: Drug: Belinostat
Drug: Isotretinoin
Other: Pharmacological Study

First Posted Date: 2006-06-08

Last Posted Date: 2018-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00334789

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 2 locations

Nutritional Intervention to Prevent Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Dietary Supplement: Placebo for DHA
Dietary Supplement: DHA Treatment

First Posted Date: 2006-06-05

Last Posted Date: 2020-04-29

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 99

Registration Number: NCT00333554

Locations: 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
University of Iowa Health Care, Iowa City, Iowa, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy